Posted on

Novamind Doubles in Size, Adds Four New Psychedelic Mental Health Clinics

New clinics represent the first phase of Novamind’s national expansion strategy

TORONTO, ON / ACCESSWIRE / May 4, 2021 / Novamind Inc. (CSE: NM | OTC: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it will open four new Cedar Psychiatry clinics (the “New Clinics”), doubling its network to eight total locations.

The expanded capacity from the New Clinics is forecasted to increase Novamind’s patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits anticipated in 2021, a 225% increase.

Novamind has begun construction on three of the New Clinics and leased a fourth additional property. Scheduled to open between July and September 2021, the New Clinics represent the initial phase of Novamind’s national expansion strategy whereby the Company is replicating the successful operating track record of its current clinics in Utah, at scale, ahead of its expansion into other American states in 2021.

Novamind’s investment in the expansion of its clinic network follows a significant increase in demand from clients for mental health services to address existing unmet needs and the effects of the Covid-19 pandemic. All Cedar Psychiatry clinics currently have a 2-week wait time for booking new appointments.

The New Clinics will each offer a range of treatments including ketamine-assisted psychotherapy, Spravato™, Cognitive Behavioral Therapy (CBT) and Transcranial Magnetic Stimulation (TMS). The Draper, Murray, and Salt Lake City locations will also offer opportunities for patients to participate in clinical trials for psychedelic medicine that are led by Cedar Clinical Research, Novamind’s clinical research arm. The Park City location will uniquely serve as both a clinic and a retreat center offering therapeutic psychedelic experiences, leveraging its community’s reputation as a world-class destination.

“We are doubling the size of our clinic network six months ahead of schedule, with the added capacity enabling us to scale to 65,000 client visits in 2021,” said Yaron Conforti, CEO and Director of Novamind. “Expect continued and aggressive growth as we expand Novamind’s clinic network and clinical research infrastructure ahead of the FDA’s anticipated approvals of MDMA and psilocybin.”

Novamind is making additional strategic investments in the infrastructure required to support the rapid growth in client volumes at its clinics. A new, dedicated call center is under construction and will enhance Novamind’s network of eight clinics by improving communications with clients and referring physicians, as well as facilitating the significant increase in processing of insurance reimbursements. Additional details for each of the New Clinics and the call center will be announced in subsequent press releases.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

Posted on

Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC

Events subsequent to quarter end include $40.25 million financing and Phase 1 clinical trial

VANCOUVER, BC, April 29, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its second quarter financial results for the three months ended February 28, 2021.

In the second quarter, Numinus raised significant funds and advanced its compassionate access trial portfolio, acquisition strategy and innovation agenda while creating a strong foundation for long-term, sustainable growth across all lines of business.

All financial results are reported in Canadian dollars unless otherwise stated.

Q2 2021 Highlights:

  • Achieved cash balance of $28.5 million as at February 28, 2021
  • Completed $17.25 million bought deal public financing and exercised more than $14.5 million in warrants and options
  • Realized net loss of $4.2 million compared to $2.1 million in Q2 2020
  • Reported revenue of $231,507 compared to $259,489 in Q2 2020
  • Completed acquisition of Montreal-based Mindspace Wellbeing
  • Signed lab services agreement with Optimi Health to advance R&D
  • Announced collaboration with Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC) and key advancements for the compassionate access trial for MDMA-assisted therapy for post-traumatic stress disorder
  • Completed the first legal extraction of Psilocybe mushrooms by a Canadian public company
  • Obtained the Orbitrap Exploris 120 mass spectrometer instrument to accelerate R&D

Highlights Subsequent to Quarter End:

  • Completed $40.25 million bought deal public financing
  • Raised $1.48 million due to the exercise of warrants and options
  • Achieved several milestones for the compassionate access trial with Syreon Corporation for Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders
  • Received Health Canada license amendment to allow for the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelics including ketamine, LSD, mescaline, DMT, and MDMA
  • Announced a 7,500-square-foot expansion of Numinus Bioscience’s research laboratory
  • Continued research activities related to psilocybin extraction of Psilocybe mushrooms as part of the Company’s research program
  • Announced Phase 1 clinical trial of natural psilocybin mushroom extraction prepared at Company lab in partnership with KGK Science

Commentary and Outlook

“Q2 was a landmark quarter for Numinus, and we were pleased to close the period with a strong cash position, stable balance sheet and robust pipeline of announcements across all lines of our business,” said Payton Nyquvest, President, CEO, and Chair, Numinus. “In addition, we were pleased to welcome Mindspace Wellbeing, its exceptional leadership team and more than 30 therapists into our family of clinics.”

“As of today, we are well set up for the balance of the fiscal year with $65 million in cash, a strategy for future M&A, leadership in lab licensing, world-class clinical trial partnerships and a uniquely integrated approach to psychedelic production, research and clinic care. Our focus remains on investments in our growth initiatives, and we are confident that we will continue advancing our leadership position in the implementation of evidence-based, psychedelic-assisted therapy,” added Mr. Nyquvest. “I want to thank our team, partners and shareholders for helping us achieve these important milestones less than one year after our public markets debut, and for supporting our mission to empower people to heal and be well.”

Numinus continues to generate revenue in its first operational year as a public company and is actively investing capital to further its growth initiatives. The Company expanded its psychedelic testing capabilities and services at its Numinus Bioscience laboratory, and has undertaken renovations at its Vancouver clinic to offer a wider variety of therapy options and prepare for psychedelic-assisted therapy delivery and compassionate access trials later in 2021. In addition, the Company started generating revenue from the closing of the Mindspace acquisition in Q2.

With the capital raised in Q2 and subsequently in Q3, Numinus has a strong cash position that will be invested to support lab initiatives, Vancouver clinic renovations and new hires, including positions in business development, M&A, marketing and communications, and mental health and psychedelic-assisted therapy services.

Selected Financial Results for Q2 2021

For the three months ended For the six months ended
February 28, 

2021

 February 29, 

2020

 February 28, 

2021

 February 29, 

2020
Revenue $231,507 $259,489 $460,695 $393,904
Cost of revenue (291,231) (155,031) (558,554) (223,229)
Gross profit (59,724) 104,458 (97,859) 170,675
Expenses (4,170,659) (2,135,273) (6,080,588) (3,092,750)
Loss before other items (4,230,383) (2,030,815) (6,178,447) (2,922,075)
Other items (7,489) (37,133) 11,838 (50,884)
Loss before income taxes (4,237,872) (2,067,948) (6,166,609) (2,972,959)
Income tax – – – (6,240)
Loss and comprehensive loss for the period $(4,237,872) $(2,067,948) $(6,166,609) $(2,979,199)
For the six months ended
February 28, 

2021

 February 29, 

2020
Cash used in operating activities $(6,212,845) $(526,861)
Cash generated by (used in) investing activities (71,847) 53,552
Cash generated by financing activities 33,238,449 584,803
Change in cash during the period 26,953,757 111,494
Cash, beginning of period 1,627,329 89,987
Cash, end of period $28,581,086 $201,481

Numinus’ condensed consolidated interim financial statements for the period ended February 28, 2021 and related management’s discussion and analysis are available on Numinus’ website at numinus.ca and under the Company’s profile on SEDAR at www.sedar.com.

About Numinus

Numinus Wellness (TSX-V: NUMI) empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice, and building the foundation for a healthier society.

Learn more at numinus.ca, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “believes”, “intends”, “Anticipates” or “does not anticipate”, or “believes” or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would” or “be” taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

For further information:

John Fong, Chief Financial Officer and Corporate Secretary, Numinus Wellness Inc., ir@numinus.ca

For media inquiries: Maggie Hall, Kaiser & Partners, maggie.hall@kaiserpartners.com

Posted on

Complex Biotech Discovery Ventures Hires New Lead Chemist

VANCOUVER, BC, April 28, 2021 /PRNewswire/ – Delic Holdings Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce that its acquisition target, Complex Biotech Discovery Ventures Ltd. (“CBDV”), a licensed cannabis and psilocybin research laboratory specializing in chemical analytics, extraction optimization, and process design, has hired Dr. Eric Janusson as Lead Chemist.

Dr. Eric Janusson is an analytical organometallic chemist specializing in real-time methods for the quantification and characterization of sensitive chemical intermediates. A long-time resident of Vancouver Island, Dr. Janusson received his Ph.D. in analytical chemistry at the University of Victoria in 2017 under the direction of Professor Scott McIndoe. After completing his studies, Dr. Janusson held a postdoctoral scholar position with the Cronin Group at the University of Glasgow where he developed an interest in machine learning, statistical modelling, self-assembly of inorganic nanoparticles, automated synthesis and robotics, as well as ion mobility mass spectrometry. Dr. Janusson was a postdoctoral researcher at the University of Glasgow, Scotland from 2017 to 2019 in the Cronin Group. After completing his contract with the Cronin Group, he continued on as an associate member until March 2021. Dr. Janusson joined CBDV in 2021 to spearhead the analytical chemistry efforts of the company and further develop high-quality analytical methods for cannabis and psilocybin research.

As Lead Chemist, Dr. Janusson’s function and main duties within the company include:

  • Lead analytical chemistry efforts
  • Lead method development for cannabis and mushroom testing
  • Provide input on scientific leadership and strategic direction for the company
  • Build alliances and partnerships with other scientific experts/organizations

Dr. Markus Roggen, Director of Delic Corp & Founder of CBDV commented, “We are excited to have Eric join us. He brings a lot of expertise in analytical chemistry and new perspectives to the team. Eric is instrumental to combine our analytical platforms with our machine learning capabilities.”

Financing

DELIC and CBDV, would also like to announce a private placement of a minimum of 3,333,333 subscription receipts of CBDV (“the Subscription Receipts”) on a non- brokered basis (“the Offering”), at a size to be determined in the context of the market.

Each Subscription Receipt will, following the completion of the Company’s transaction to acquire CBDV, entitle the holder to receive, without payment of additional consideration or taking of further action, one unit of the Company (each, a “Unit” and collectively, the “Units“), at a price CAD$0.30, with each Unit being comprised of one common share (a “CBDV Common Share“) of the Company and one common share purchase warrant of the Company (“CBDV Warrant“). Each CBDV Warrant shall be exercisable to acquire one‎ CBDV Common Share of the Company at a price of CAD$0.40 per CBDV Warrant for a period of twenty-four (24) months.

About CBDV
Complex Biotech Discovery Ventures (CBDV), based at the University of British Columbia in Vancouver, BC, is a licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Founded by award-winning chemists, Dr. Markus Roggen and UBC Professor Glenn Sammis, CBDV uses precision chemical analytics and metabolomics identification to advance the cannabis and psilocybin industries.

For media and service inquiries, please contact info@cbdvl.com. Learn more at www.cbdvl.com and follow us on LinkedIn: Complex Biotech Discovery Ventures and Instagram: @complexbiotech.

About DELIC

DELIC Always Expanding. In All Ways.

DELIC was formed in 2019 to address the growing interest in psychedelic wellness backed by science. DELIC was the ‎first psychedelic umbrella platform and is currently a trusted source for those interested in ‎psychedelic culture, psychedelic clinics, and more. ‎DELIC’s offerings include, Ketamine Infusion Center (under binding acquisition agreement), a limited liability corporation formed under the laws of Arizona and runs two ketamine clinics in Arizona and California, “Reality Sandwich”, a free public education platform providing psychedelic guides, news and ‎culture, “Meet Delic”, the first ever psychedelic wellness summit, and “The Delic”, an e-commerce lifestyle brand. ‎For more information, check out www.deliccorp.com.

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of DELIC’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to, closing of the transaction with CBDV, the private placement and conversion of subscription receipts, the growth and business of CBDV, potential earn out payments, anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics), the continued emergence of psychedelics from stigmas, the ability of the Company to maintain sensible messaging, the ability of the Company to avoid dogmatic practices and binary rhetoric‎, the ability of DELIC to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, DELIC is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of DELIC to be ‎materially different from those ‎expressed or implied by such information and statements. In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, DELIC has made certain ‎assumptions. Among the key factors that could cause actual ‎results to differ materially from those projected in the ‎forward-looking information and statements are the ‎following:‎ the ability to consummate the Transaction; the ability to satisfy the conditions to closing of the Transaction on the proposed terms and schedule; the potential impact of the announcement or consummation of the acquisition on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion of management time on the Transaction.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although DELIC believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and DELIC does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Posted on

Lobe Sciences Enters into LOI with Core One Labs to Form a Joint Venture for the Clinical Development of Biosynthetic Psilocybin

Vancouver, British Columbia–(Newsfile Corp. – April 28, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to announce it has entered into a non-binding letter of intent dated April 27, 2021 (the “Agreement“) with Core One Labs Inc. (CSE: COOL) (“Core One Labs“) to pursue the formation of a joint venture involving the development, regulatory approval and marketing of biosynthetic psilocybin and other psychedelic compounds (the “Joint Venture“).

“Lobe is pleased to pursue a partnership with Core One Labs, as we continue our business expansion efforts within the rapidly growing psilocybin and psychedelics space,” said Philip Young, CEO of Lobe. “A joint venture is the logical next step for us as it has the potential to provide cGMP grade psilocybin for use in clinical studies we plan to initiate in the future.”

 

The Agreement proposes that Core One Labs would develop and manage the cGMP production and delivery of biosynthetic psilocybin and Lobe would be responsible for the clinical development, and commercialization of the product(s). Vocan Biotechnologies Inc. (“Vocan“), a wholly-owned subsidiary of Core One Labs, would produce the biosynthetic psilocybin and other psychedelic compounds to be used. Vocan has identified a patentable method of producing psilocybin, the active ingredient in psychotropic mushrooms.

 

The structure and terms of the Joint Venture remains subject to negotiation between the parties. The Joint Venture is subject to a number of other conditions, including but not limited to, legal and regulatory due diligence by the parties, negotiation and execution of a definitive agreement (the “Definitive Agreement“) with binding terms and conditions for the Joint Venture, including, but not limited to, customary representations and  warranties,  royalty structure  for  payments by Core  One  Labs for  product  sales initiated  by Lobe,  the  price of biosynthetic psilocybin to Lobe, the production schedule of Core One Labs and the timeframe for product order fulfillment and delivery, which shall supersede the Agreement and receipt of applicable corporate and regulatory approvals. There can be no assurance that the Joint Venture will be completed as proposed herein or at all.

About Lobe Sciences Ltd.

 

Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.

Philip J Young, CEO info@lobesciences.com Tel: (949) 505-5623

 

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

 

Disclaimer for Forward Looking Statements

 

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, the proposed Joint Venture with Core One Labs and products expected to be developed, approved and commercialized, statements regarding research and development using psychedelic compounds, the development of innovative devices and delivery mechanisms to improve mental health and wellness, the initiation of future clinical trials, and business expansion initiatives, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including that the expected benefits to be derived from the proposed joint venture with Core One Labs may not materialize as expected, including that the Joint Venture may be unsuccessful in developing, obtaining

 

regulatory approval and commercializing any products and/or the risk that the Company may not realize a return on its investment in the Joint Venture, changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; the completion of a Definitive Agreement, that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward- looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

4/28/2021 4:36:00 PM

Posted on

Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab

Clinical trial will evaluate safety and psychoactive properties of natural Psilocybin product extracted and formulated at 7,000-square-foot laboratory in British Columbia, Canada

VANCOUVER (April 26, 2021) – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that it has formed a partnership with KGK Science, a leading contract research organization with expertise in natural products, to undertake a new Psilocybin extraction clinical trial.

The Phase 1 trial will enroll 14 human volunteers and assess the safety and psychoactive properties of a Psilocybe mushroom product extracted and formulated at the Numinus Bioscience lab in British Columbia, Canada. Successful completion of the landmark trial would result in safety and efficacy data for a natural Psilocybin product which could subsequently be used for further research and government-approved special access or compassionate access programs.

In addition, the trial would support Canada’s leadership in the safe production of a key psychedelic that has shown promise in treating mental health conditions including depression, end of life anxiety and substance use disorders, when used in conjunction with a standardized psychotherapy program under clinical supervision.

“This Phase 1 trial supports our mandate to improve access to safe, evidence-based psychedelic-assisted therapies in Canada and around the world,” said Payton Nyquvest, CEO, Numinus. “Through this trial, we expect to demonstrate that Numinus is well ahead in the development of natural Psilocybin therapeutics that are safe for humans and can be used to support our sector’s growth through sales to other research organizations, the creation of new intellectual property, and the ability to conduct our own Phase 2 and Phase 3 clinical trials, if we choose to do so.”

“We’re thrilled to help lead ground-breaking clinical work using Psilocybin,” said Najla Guthrie, President & CEO, KGK Science. “Our team’s expertise in the area of natural health products makes us uniquely positioned to contribute to the burgeoning psychedelics industry.”

Numinus is less than three years old, but already has a history of innovation in psychedelics. Numinus completed the first legal extraction of Psilocybe mushrooms in Canada by a public company for research and development purposes, and completed the cultivation and harvest of the first legal flush of Psilocybe mushrooms.

“We believe there are several likely advantages to naturally occurring Psilocybin therapeutics that will make them attractive for researchers and consumers alike,” said Sharan Sidhu, Science Officer and General Manager at Numinus Bioscience. “We are confident that this trial will document that natural Psilocybin extractions meet health regulator requirements for safety, efficacy and quality, and ultimately enable the establishment of better access to this medicine.”

“We are excited to see Health Canada grant legal exemptions for certain patients to use Psilocybin alongside psychotherapy in situations when other treatments have failed, and to consider revisions to its Special Access Programme that could allow Canadian patients access to psychedelic medications when other drugs have been unsuccessful,” added Dr. Evan Wood, Chief Medical Officer, Numinus. “As research interest and the potential for increased compassionate access to Psilocybin grows, it is imperative that patients have access to safe, pharmaceutical-grade supply that offers consistent psychoactive properties at scale. With this trial, we are taking the first steps towards that goal.”

Currently, Numinus is also partnering with Syreon Corporation, a global contract research organization, to undertake a single-arm, open-label compassionate access trial that will assess the efficacy and safety of Psilocybin-assisted motivational enhancement therapy using a synthetic Psilocybin product. The study will contribute to a growing body of research to inform larger randomized controlled trials for these indications. The study will take place in Vancouver and will enroll 30 individuals with opioid, stimulant and/or alcohol use disorders.

###

About Numinus

Numinus Wellness (TSX-V; NUMI) empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice, and building the foundation for a healthier society.

Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.

About KGK
As a global Contract Research Organization (CRO), KGK Science performs a productive and pioneering role in the realm of scientific study. For over two decades, it has offered well-designed, customized solutions to each of its clients, consolidating its scientific, clinical, commercial, and regulatory abilities into one full-service package. Equipped with state-of-the-art technologies, novel research techniques, and a seasoned team of thought leaders, KGK remains at the forefront of its industry. And, by seamlessly matching its experience with its drive for innovation, this CRO is able to respond effectively to expanding trade and consumer demands.

Forward Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licences and any inability to obtain all necessary governmental approvals licences and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use of psychedelics, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers; the development and implementation of medical protocols and treatment standard operating procedures for the use of psychedelic therapies; the Company’s goals to develop and implement partnerships with research organizations and other key players in the integrative mental health industry; the Company’s ability to successfully withstand the economic impact of COVID-19; the medical benefits, safety, efficacy, dosing and social acceptance of psychedelics; the approval and/or success of compassionate access clinical trials; the cultivation and harvest of Psilocybe mushrooms; and the availability of trained personnel and medical professionals. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information:
May Lee
Communications Manager
Numinus
may@numinus.ca

For media inquiries:
Catherine Snider
Kaiser & Partners
catherine.snider@kaiserpartners.com

Posted on

Lobe Sciences Appoints Benjamin Kelmendi, MD from Yale University to Scientific Advisory Board

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

Vancouver, British Columbia–(Newsfile Corp. – April 20, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

 

Philip Young, CEO and Director of Lobe stated, “We are extremely pleased to welcome Ben to our Scientific Advisory Board. Dr. Kelmendi will add significant relevant experience to the team as we move through preclinical studies into human clinical trials. We look forward to working with Dr. Kelmendi and the team at the Yale Psychedelic Science Group.”

 

Dr. Kelmendi is a board-certified psychiatrist and is an Assistant Professor in the Department of Psychiatry at the Yale University School of Medicine and is also a co-founder of the Yale Psychedelic Science Group. His primary clinical expertise is in post-traumatic stress disorder (“PTSD“), depression, obsessive-compulsive disease (“OCD“). He leads a research program focused on the therapeutic potential of psychedelic medicines, across a range of psychiatric diagnosis. He is currently investigating the effects of psilocybin on the neurocircuitry implicated in the development, maintenance, and treatment of patients with OCD. He is also exploring the effects of MDMA on brain activation and neural network organization in PTSD to understand the relationship between MDMA-induced neural changes and the acute cognitive and behavioral effects of the drug.

 

Benjamin Kelmendi, MD stated, “The re-emergence of psychedelic medicine as a respected area of research has undergone a protean trajectory. In the most recent revival of investigations into potential therapeutic benefits of long-maligned psychedelic substances, we are now revisiting past work in this area completely differently with a heightened sense of scientific responsibility, knowledge, and technology. I am excited by the renewed interest in the potential of psychedelic substances, both as therapeutic agents and as tools to provide insight into the human brain and mind’s inner workings. I look forward to working with the Advisory Board and the Lobe team as we all work together to ethically develop psychedelic therapies for mental illness.”

About Lobe Sciences Ltd.

 

Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.

Philip J Young, CEO info@lobesciences.com Tel: (949) 505-5623

 

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

 

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, the development of innovative devices and delivery mechanisms to improve mental health and wellness, moving through preclinical studies to human clinical trials, and working with

 

the team at the Yale Psychedelic Science Group, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

4/20/2021 10:54:00 AM

Posted on

Biotech Companies Driving Psychedelics Industry Forward with Key Research

Published at PRnewswire.com

‍

FN Media Group Presents Microsmallcap.com Market Commentary

NEW YORK, April 13, 2021 /PRNewswire/ — As an urgent public mental health crisis forces research institutions and governments to seriously examine unconventional mental health solutions, psychedelic assisted therapies are showing huge potential. Now, biotech companies have seen the opportunity, and psychedelics companies are diving into further research to seek out mental health solutions for conditions such as depression, PTSD, and suicidal ideation. Some companies like Mydecine Innovations Group (NEO:MYCO) (OTCPK:MYCOF), Compass Pathways (NASDAQ:CMPS), Minerco Inc. (OTCPK:MINE), Numinus Wellness (TSXV:NUMI) (OTCPK:LKYSF), and Seelos Therapeutics (NASDAQ:SEEL) are also looking into natural medicine initiatives to improve the quality of life of individuals struggling with mental health disorders

Mydecine Innovations Group Develops Lead Novel Drug Candidates

As biotech and life sciences companies become the driving force behind psychedelic research, Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) is becoming a leader in this space. Mydecine is dedicated to the research, development, and commercialization of psilocybin-based therapies. The company holds a full Health Canada Schedule 1 Controlled Drugs and Substances Dealer’s Licence and operates a state-of-the-art mycology lab in Denver, Colorado. The company has facilitated numerous studies and development initiatives in-house and in collaboration with top research institutions.

On April 7, Mydecine announced that the company’s research team has developed four lead novel drug candidates and that Mydecine is currently preparing for Pre-Investigational New Drug (IND) meetings with the FDA and Health Canada. The four compounds include pure psilocybin from natural fungal sources, an entactogenic compound created with the goal of reducing harm and improving the safety profile compared to traditional MDMA, a psilocybin-based formula with reduced potential to trigger anxiety in patients, and a tryptamine compound that could be delivered transdermally with precision dosing and a shortened duration.

“Our first four novel drug candidates deliver on our long-term strategic road map for drug development with regular milestones that iteratively add value over time. By increasing the complexity of these compounds, we are increasing layers of patents applied, which in turn, also adds pharmaceutical value to the drug candidates,” Mydecine Co-Founder and CEO Joshua Bartch said in the company’s release. “The promise of these molecules is undeniable. By providing scalable, more stable compounds and delivery mechanisms for research and development, it means that new treatments for previously untreatable mental illnesses are close at hand.”

On March 23, Mydecine announced that the company had graduated to the NEO Exchange. Bartch said in Mydecine‘s release that the move will increase transparency and visibility for the company as it pursues its research and development goals.

“Mydecine is paving the way for incredible breakthroughs and we are thrilled to support their success as the Company’s listing exchange of choice,” Jos Schmitt, President and CEO of NEO commented in Mydecine‘s release. “Psychedelic therapeutic treatments have the potential to offer life-altering relief to millions of people around the world who suffer from mental health and addiction issues. We look forward to providing Mydecine with enhanced visibility and greater access to capital on our tier-one exchange so they can continue the great work they are doing.”

Biotech Companies Gear Up for Key Research

Across the industry, psychedelics-focused biotech companies are gearing up for research that could help shape the future of mental health treatment. On March 9, Numinus Wellness (TSXV:NUMI) (OTC:LKYSF) announced plans to significantly expand its psychedelics research laboratory by the end of the year.

Compass Pathways (NASDAQ:CMPS) announced on March 23 that the company had been granted two new patents by the US Patent and Trademark Office covering synthetic psilocybin formulations developed by Compass for treatment of major depressive disorder and treatment-resistant depression. The company says that these patents represent a critical milestone in its efforts to establish a new evidence-based option to help patients with depression and will aid the company’s clinical research.

In January, Jamaica-based biotech company Minerco Inc. (OTC:MINE) was acquired by a specialized investment firm with plans to immediately transition the company to the psilocybin therapeutics market with a focus on research and development. Earlier in January, Minerco announced that the company had partnered with Lazurus Holistic to serve as psilocybin experts to grow and develop a unique strain of mushrooms specific to Jamaica.

Biopharmaceutical company Seelos Therapeutics (NASDAQ:SEEL) announced on March 5 that the company had completed its enrollment of patients in Part one of its registrational Proof of Concept study of intranasal racemic ketamine for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder.  The company says that it expects to release key open-label data by the second quarter of 2021

Promising research is driving momentum in the psychedelic therapeutics industry, and companies like Mydecine Innovations Group are building on that momentum with their own research and development.

Click here to find out more about Mydecine Innovations Group.

Disclaimer:  Microsmallcap.com (MSC) is the source of the Article and content set forth above. MSC owns and operates Streetsignals.com.  References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Mydecine Innovations Group Inc.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

‍

Posted on

Delic Provides First Quarter 2021 Shareholder Update

VANCOUVER, BC, April 12, 2021 /PRNewswire/ – Delic Holdings Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to provide the following shareholder update on its operations for the first quarter of 2021.

The first quarter of 2021 has been transformative and expansive as DELIC has entered into new sectors of this nascent industry. From early beginnings in media with Reality Sandwich, Meet DELIC, & DELIC Radio, DELIC now has begun to execute its M&A strategy by entering into binding agreements with Ketamine Infusion Center (“KIC”), with their clinics located in California and Arizona, and of Complex Biotech Discovery Ventures (“CBDV”) in Vancouver, and more.

Acquisition Transactions:

Ketamine Infusion Center

On February 5th, 2021 DELIC announced the acquisition of KIC, who over the last 3 years have overseen over 4,000 ketamine infusion treatments delivered, all while seeing revenues increase to over USD$1.5mm. The KIC team has been in the clinic and medical space for over 15 years scaling and operating clinics and hospitals across the United States.

KIC exclusively administers IV Ketamine infusions, which allows them to master the science behind this unique psychedelic therapy. They utilize a state of art electronic medical record system specifically designed for KIC which allows them to track patient outcomes seamlessly. With this effective monitoring tool they gain full representation of progress when it comes to assessing each individual patient. KIC believes that quality of life should not be accomplished by socioeconomic status, so they work diligently to utilize insurance benefits of patients to provide crucial treatment. With 2 clinics already operating in Arizona and California, DELIC plans to help KIC expand to other states in the near future with a goal of adding 12 to 18 clinics in the next 12 to 18 months.

Closing of the transaction is subject to customary conditions and is expected to close in the second quarter of 2021.

Complex Biotech Discovery Ventures

On February 25th, 2021 DELIC announced its acquisition of CBDV (to be renamed DELIC labs), which is a licensed (granted a “Section 56 exemption” by Health Canada) psilocybin and cannabis research lab focused on extraction, analytical testing, and chemical process development. Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Glenn Sammis, CBDV supports the psycheDELIC industry with high precision chemical analytics and metabolomic identification.

CBDV is working to solve the current and future problems of the cannabis and psilocybin industries. CBDV utilizes their talented team and collaborative relationships with partner organizations, industry leaders, and academia. These collaborative efforts enable them to expand knowledge on complex subjects and work on a wide array of chemistry and  health and business issues. They are committed to broadening their horizons by ultimately building a stronger foundation of expertise for DELIC, and the sector as a whole.

Closing of the transaction is subject to customary conditions and is expected to close in the second quarter of 2021.

Homestead Brand

On top of the acquisitions of KIC and CBDV, on March 4th 2021 DELIC announced the acquisition of Homestead which is a legacy counterculture distributor of psychedelic media and creator of one of the first self-contained psilocybin mushroom grow kits. The acquisition of Homestead is an exciting one as It shows how DELIC is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead not only sold tens of thousands of mushroom kits globally but also was one of the earliest distributors for High Times Holdings and many other counter culture publications.

The Homestead acquisition allows DELIC to increase their product offering on their owned website Reality Sandwich (realitysandwich.com), which most recently hit record average monthly traffic of over 200,000 unique visitors, and over 2.6 million active readers in 2020. Through Homestead’s extensive intellectual property and heritage brand, DELIC anticipates to revive the “at home EZ Grow experience” targeted at the Reality Sandwich consumer. Product launch is expected in the later half of Q2 2021, and the new mushroom at home grow kit will have a modern interpretation of the company’s history and will include everything a consumer needs to be an at home mycologist – pre-sterilized and as easy as mixing the core ingredients provided. In addition to the mushroom kit being offered, consumers will also be able to purchase other complementary products to the kit to enhance their experiences and to become better mycologists.

Launch of Meet DELIC Conference:

DELIC will announce our new date for Meet Delic, the premier psychedelic wellness event of the year, in early April. Come and experience what’s new in psychedelic wellness, connect with the community and expand your horizons. Happening in sunny Las Vegas, Nevada. We can’t wait to Meet you. For more information visit MeetDelic.com.

Matt Stang, Founder and CEO commented “What’s in store for the rest of 2021? DELIC is focused on expanding its M&A strategy well beyond its early acquisition targets. We look to utilize our mental health platform to assist studies and increase the intellectual properties born from CBDV’s research, (to be renamed DELIC Labs), and our acquisition of Ketamine Infusion Center’s to expand not only across the US, but Canada also, with the goal to expand clinics from 2 current clinics to up to 12 in the next 12 to 18 months. As we push forward on this exciting new path and transformation within the psychedelic space. We strive to become a leader in the health and wellness sector and ultimately help people. I am extending a big thank-you to the continued support received from our shareholders. We’re just getting started.”

About DELIC

DELIC Always Expanding. In All Ways.

DELIC was formed in 2019 to address the growing interest in psychedelic wellness backed by science. DELIC was the ‎first psychedelic umbrella platform and is currently a trusted source for those interested in ‎psychedelic culture, psychedelic clinics, and more. ‎DELIC’s offerings include, Ketamine Infusion Center (under binding acquisition agreement), a limited liability corporation formed under the laws of Arizona and runs two ketamine clinics in Arizona and California, “Reality Sandwich”, a free public education platform providing psychedelic guides, news and ‎culture, “Meet Delic”, the first ever psychedelic wellness summit, and “The Delic”, an e-commerce lifestyle brand. ‎For more information, check out www.deliccorp.com.

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of DELIC’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to, closing of the Transaction, the growth and business of CBDV, potential earn out payments, anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics), the continued emergence of psychedelics from stigmas, the ability of the Company to maintain sensible messaging, the ability of the Company to avoid dogmatic practices and binary rhetoric‎, the ability of DELIC to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, DELIC is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of DELIC to be ‎materially different from those ‎expressed or implied by such information and statements. In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, DELIC has made certain ‎assumptions. Among the key factors that could cause actual ‎results to differ materially from those projected in the ‎forward-looking information and statements are the ‎following:‎ the ability to consummate the Transaction; the ability to satisfy the conditions to closing of the Transaction on the proposed terms and schedule; the potential impact of the announcement or consummation of the acquisition on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion of management time on the Transaction.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although DELIC believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and DELIC does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Posted on

Psychedelics Company Silo Wellness Expands its Shareholder Base to Europe by Commencing Trading on the German Börse Frankfurt (FRA) Exchange Under Ticker Symbol “3K70”

TORONTO, April 12, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (CSE:SILO) (FRA:3K70), a wellness company in the psychedelics and functional mushroom marketplaces is pleased to announce that trading of its common shares has expanded to include overseas listing on the German Börse Frankfurt (FRA) exchange platform.

The commons shares of Silo Wellness securities began trading on Friday, April 9, 2021 on the FRA under ticker symbol 3K70 and registered under WKN: A2QQTP and/or ISIN: CA8271241082.

“Expanding our shareholder base more broadly into the European market by commencing trading on the Frankfurt exchange is an important milestone for Silo Wellness as we continue to broaden our international presence,” said Douglas K. Gordon, Chief Executive Officer of Silo Wellness.  “By listing on the FRA, a wider audience of investors will now be able to actively participate in the growth of Silo Wellness as we continue to deliver on our mission as well as grow on a global basis.”

About Silo Wellness
The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion. Silo Wellness intends to introduce new, safe and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.

Since its inception, Silo Wellness’ activities have focused on: (1) development of psilocybin-free functional mushroom tinctures; (2) the development of the formulation of a psilocybin nasal spray in Jamaica; and (3) offering of Jamaican and Oregon psychedelic wellness retreats as well as the cultivation of psychedelic mushrooms in Jamaica. None of Silo Wellness’ products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.

For further information, please contact: www.SiloWellness.com

Silo Wellness Investor Relations:
(604) 343-2724
IR@empiregroupir.com

Media Relations:
Stuart Kirby, VP of Marketing & Communications
press@silowellness.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: listing of the common shares of Silo Wellness on the CSE and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Posted on

Lobe Sciences Appoints Ilan Hayman to Advisory Board

Vancouver, British Columbia–(Newsfile Corp. – April 6, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to announce the appointment of Mr. Ilan Hayman, B.IS, ITIL Cert, M. ProjMngt to its Advisory Board.

Philip Young, CEO and Director of Lobe states, “We are very pleased to welcome Ilan to our Advisory Board. Ilan’s operational experience in healthcare will complement our research and development expertise with psychedelic medicine. Mental health is a priority worldwide and psychedelic medicine has been at the forefront of research initiatives. Ilan’s association with Mind Medicine Australia will allow Lobe to be introduced to this organization’s mandate and we are excited about fostering this relationship. Ilan is our latest addition to supplement our team and enhance our international reach. We are committed to strengthening our team and relationships to build the business and achieve the Company’s key priorities.”

 

Ilan is an experienced operations executive with a demonstrated history of working in the healthcare industry and IT sector. Since 2019 he has been the Operations Manager with Mind Medicine Australia (“MMA“). MMA is a charity that helps to alleviate the suffering caused by mental illness in Australia through expanding the treatment options available to medical practitioners and their patients by establishing safe and effective psychedelic assisted treatments to cure a range of mental illnesses. The charity was founded by Tania de Jong AM and Peter Hunt AM. It acts as a central node between stakeholders to facilitate the delivery of psychedelic-assisted treatments in Australia. This is accomplished by bringing together the key stakeholders including academia, government, medical practitioners, technology, philanthropy, and culture. Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses and supports and funds clinical psychedelic research, conducted by independent institutions and affiliates, working towards regulatory-approved and evidence-based psychedelic-assisted therapies.

Ilan Hayman states, “It is a pleasure to join Lobe during this exciting time for the company. With the current preclinical trials with the University of Miami and the development of its nasal mist delivery device I look forward to working with the team to position the company as a leader in the space.”

 

Prior to joining MMA, Ilan oversaw a group of national medical centers and was involved in general management of healthcare businesses including a private cosmetic surgery chain and led the development and commercialization of a line of skincare products.

 

Ilan is a board member for several not-for-profit organizations. He also holds Bronze and Silver Duke of Edinburgh awards and brings along a unique set of community and industry related experience. Ilan received his Bachelor Degree in Information Systems from the Macquarie University Australia as well as a Masters Degree focused on Project Management from Torrens University Australia.

About Lobe Sciences Ltd.

 

Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.

Philip J. Young

Chief Executive Officer and Director info@lobesciences.com

Tel: (949) 505-5623

 

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

 

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, the development of innovative devices and

 

delivery mechanisms to improve mental health and wellness, the ability to foster a relationship with Mind Medicine Australia and enhance its international reach, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

4/6/2021 10:53:00 AM